Leukocyte Adhesion Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Rocket Pharmaceuticals
1 program
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)N/AGene Therapy1 trial
Active Trials
NCT06282432Active Not Recruiting9Est. Oct 2036

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Rocket PharmaceuticalsLong-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

Clinical Trials (1)

Total enrollment: 9 patients across 1 trials

NCT06282432Rocket PharmaceuticalsLong-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

Start: Mar 2022Est. completion: Oct 20369 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space